Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 449Neoplasms, Plasma Cell 69Lymphoma, Mantle-Cell 66Recurrence 65Lymphoma 65Lymphoma, Non-Hodgkin 43Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Lymphoma, Large B-Cell, Diffuse 34Waldenstrom Macroglobulinemia 33Lymphoma, B-Cell, Marginal Zone 30Leukemia, Lymphocytic, Chronic, B-Cell 28Neoplasms 24Immunoglobulin Light-chain Amyloidosis 24Carcinoma, Non-Small-Cell Lung 24Leukemia 21Hodgkin Disease 17Hematologic Neoplasms 16Lymphoma, B-Cell 14Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 13Lymphoma, Large-Cell, Anaplastic 13Immunoblastic Lymphadenopathy 12Breast Neoplasms 12Mycosis Fungoides 11Lymphoma, T-Cell, Cutaneous 11Lymphoma, Large-Cell, Immunoblastic 11Congenital Abnormalities 11

Interventions

Lenalidomide 2Dexamethasone 2Bortezomib 2ruxolitinib 1posaconazole 1darinaparsin 1carfilzomib 1belinostat 1Stem Cell Transplantation 1SCIO-469 1Low-Level Light Therapy 1Hydroxyurea 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Marrow Neoplasms × Bortezomib × Clear all
NCT01286077 2016-05-30

Velcade Consolidation Bone Study

Janssen-Cilag International NV

Phase 2 Completed
106 enrolled 19 charts
Plasma cell

Multiple Myeloma, Bone Marrow Neoplasms

NCT00908232 2015-01-15

SEQUENTIAL

Janssen-Cilag International NV

Phase 2 Completed
163 enrolled 11 charts
Plasma cell

Multiple Myeloma, Disease Progression, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡